FDC gets USFDA nod for Ofloxacin Otic Solution
Mumbai: Pharma firm FDC Limited has recently announced that the company has received approval from the United States Food and Drug Administration (USFDA) for Ofloxacin Otic Solution, 0.3%.
"This is to inform you that, the Company has been granted ANDA approval by USFDA, for Ofloxacin Otic Solution, 0.3%," the company said in a BSE filing.
An abbreviated new drug application contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.
Read also: Covid-19: FDC launches first Favipiravir Oral Suspension Favenza in India
Founded in 1936, FDC Limited is the pharmaceutical company headquartered in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.